"Apolipoprotein C-III" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS and CHYLOMICRON REMNANTS. Apo C-III, synthesized in the liver, is an inhibitor of LIPOPROTEIN LIPASE. Apo C-III modulates the binding of chylomicron remnants and VLDL to receptors (RECEPTORS, LDL) thus decreases the uptake of triglyceride-rich particles by the liver cells and subsequent degradation. The normal Apo C-III is glycosylated. There are several polymorphic forms with varying amounts of SIALIC ACID (Apo C-III-0, Apo C-III-1, and Apo C-III-2).
| Descriptor ID |
D053305
|
| MeSH Number(s) |
D10.532.091.400.875 D12.776.070.400.400.875 D12.776.521.120.400.875
|
| Concept/Terms |
Sialyl Apo C-III- Sialyl Apo C-III
- Apo C-III, Sialyl
- Sialyl Apo C III
- Sialyl Apolipoprotein C-III
- Apolipoprotein C-III, Sialyl
- Sialyl Apolipoprotein C III
|
Below are MeSH descriptors whose meaning is more general than "Apolipoprotein C-III".
Below are MeSH descriptors whose meaning is more specific than "Apolipoprotein C-III".
This graph shows the total number of publications written about "Apolipoprotein C-III" by people in this website by year, and whether "Apolipoprotein C-III" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Apolipoprotein C-III" by people in Profiles.
-
Pfefferkorn CM, Walker RL, He Y, Gruschus JM, Lee JC. Tryptophan probes reveal residue-specific phospholipid interactions of apolipoprotein C-III. Biochim Biophys Acta. 2015 Nov; 1848(11 Pt A):2821-8.
-
Furtado JD, Campos H, Appel LJ, Miller ER, Laranjo N, Carey VJ, Sacks FM. Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart Trial. Am J Clin Nutr. 2008 Jun; 87(6):1623-30.